Hualan Biological Engineering (002007.SZ) Earnings Analysis
Hualan Biological Engineering (002007.SZ) next reports earnings on 2026-08-29, consensus EPS 0.11 CNY. Last quarter (2026-04-27) it missed with EPS 0.13 CNY vs 0.17 CNY est (-23.5%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E 27.56.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 002007.SZ next report earnings?
| Next earnings date | 2026-08-29 |
|---|---|
| Consensus EPS estimate | 0.11 CNY |
| Revenue estimate | 0.85B |
002007.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-27 | 0.13 CNY | 0.17 CNY | -23.5% | Miss |
| 2026-03-27 | 0.09 CNY | 0.24 CNY | -62.5% | Miss |
| 2025-08-27 | 0.1109 CNY | 0.145 CNY | -23.5% | Miss |
| 2025-04-24 | 0.17 CNY | 0.17 CNY | 0% | Beat |
| 2024-08-29 | 0.1 CNY | 0.14 CNY | -28.6% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
002007.SZ valuation and analyst view
| Trailing P/E | 27.56 |
|---|---|
| Trailing EPS | 0.46911 CNY |
| Price / book | 2.04 |
| Dividend yield | 7.63% |
| Market cap | 24.08B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Hualan Biological Engineering (002007.SZ)'s next earnings date?
Hualan Biological Engineering is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.11 CNY and revenue estimate of 0.85B.
Did 002007.SZ beat earnings last quarter?
In its 2026-04-27 report, 002007.SZ posted EPS of 0.13 CNY versus a 0.17 CNY estimate — a miss of 23.5%.
What is 002007.SZ's earnings track record?
Over the last 5 reported quarters with consensus data, 002007.SZ beat estimates 1 times (20%).
What is 002007.SZ's current P/E ratio and EPS?
002007.SZ trades at a trailing P/E of 27.56 on trailing EPS of 0.46911129602701085 CNY.
What do analysts rate 002007.SZ?
002007.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.